Ribavirin
Catalog No.S2504 Synonyms: NSC-163039, ICN-1229 ,RTCA, Tribavirin
Molecular Weight(MW): 244.20864
Ribavirin, a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
3 Customer Reviews
-
(E) Left panel, Western blot showed that 20 μM Ribavirin effectively inhibits elevated Sox2 expression in irradiated SW1990 cells. Right panel, qPCR analysis showed that Sox2 mRNA level in irradiated SW1990 cells at 48 hours was lower than that in non-irradiated SW1990 cells, *p < 0.05. (F) Left panel, Western blot showed 20 μM Ribavirin inhibits elevated Sox2 expression in irradiated BxPc-3 cells. Right panel, qPCR analysis showed that there is no significant fluctuation of Sox2 mRNA in irradiated BxPc-3 cells and Ribavirin did not influence sox2 mRNA level in irradiated BxPc-3 cells.
Cancer Lett, 2016, 375(1):31-8. . Ribavirin purchased from Selleck.
Inhibition of viral replication and ensuing myocardial apoptosis ameliorates HDACI-exacerbated viral myocarditis. (A) CVB3-infected cardiac myocytes (MOI, 5) were treated with 1 μM SAHA and the indicated concentrations of ribavirin for 24 h. Cell extracts were analyzed by Western blotting with the indicated antibodies. (B) CVB3-infected cardiac myocytes (MOI, 5) were treated with 1 μM SAHA and 200 μg/ml ribavirin for 24 h. CVB3 titers in cell culture supernatants were determined by TCID50 assay (n = 4). (C) Cardiac myocytes were treated with 200 μg/ml ribavirin for 24 h. Cells morphology was examined by light microscope (scale bar, 100 μm). (D to F) CVB3-infected cardiac myocytes (MOI, 5) were treated with 2 μM SAHA in the presence or absence of 800 μg/ml ribavirin for 24 h. (D) Cell morphology was examined by light microscope (scale bar, 100 μm). (E and F) Cells were collected and stained with 7-AAD and FITC-labeled annexin V, followed by flow cytometric analysis (n = 3). (G and H) BALB/c mice were infected with CVB3 on day 0 and then simultaneously treated with SAHA (50 mg/kg) and ribavirin (100 mg/kg) or vehicle PBS daily from day 0 to day 7 p.i. (G) Survival rate was monitored daily until day 7 p.i. (n = 10). (H) Paraffin sections of heart tissues were prepared on day 7 p.i., and cardiac injury was revealed by H&E (scale bar, 50 μm). *, P < 0.05; ***, P < 0.001.
J Virol, 2015, 89(20):10512-23.. Ribavirin purchased from Selleck.
-
Establishment of Vero-rBoDV-1-Gluc cells to monitor BoDV-1 replication. (A) Dose- and time-dependent inhibitory effects of ribavirin on BoDV-1 replication. Vero-rBoDV-1-Gluc cells were treated with 20 or 40 μM of ribavirin for the indicated periods, and the luciferase activity in the cell supernatant was measured. (B) Quantification of BoDV-1 RNAs in Vero-rBoDV-1-Gluc cells treated with 20 or 40 μM of ribavirin for 72 h. Values are expressed as the mean + S.E. from 3 biological replicates. *, p < 0.05; **, p < 0.01; ****, p < 0.001.
Antiviral Res, 2017, 143:237-245. Ribavirin purchased from Selleck.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
Biological Activity
| Description | Ribavirin, a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In vitro |
Ribavirin significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although ribavirin has little effect on levels of HCV replication. Ribavirin increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. Ribavirin enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. [1] Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. Ribavirin reduces infectious poliovirus production to as little as 0. 00001% in cell culture. [2] Ribavirin's antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. [3] Ribavirin markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). Ribavirin inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. [4] Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. Ribavirin is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. Ribavirin is thought to induce a switch in T-helper cell phenotype from type 2 to type 1. [5] |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Data |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assay |
|
Protocol
Solubility (25°C)
| In vitro | DMSO | 49 mg/mL (200.64 mM) |
|---|---|---|
| Water | 49 mg/mL (200.64 mM) | |
| Ethanol | Insoluble |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 244.20864 |
|---|---|
| Formula | C8H12N4O5 |
| CAS No. | 36791-04-5 |
| Storage | powder |
| in solvent | |
| Synonyms | NSC-163039, ICN-1229 ,RTCA, Tribavirin |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT03889106 | Recruiting | Drug: Ribavirin | Lassa Fever | University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England | March 1 2019 | -- |
| NCT03585725 | Recruiting | Drug: Ribavirin | Follicular Lymphoma|Mantle Cell Lymphoma | Weill Medical College of Cornell University | September 26 2018 | Early Phase 1 |
| NCT02940691 | Terminated | Drug: Grazoprevir/elbasvir | Hepatitis C | Kirby Institute | May 1 2017 | Phase 4 |
| NCT02945150 | Active not recruiting | Drug: grazoprevir plus elbasvir (fixed dose combination) | Renal Failure | Massachusetts General Hospital|Merck Sharp & Dohme Corp. | February 1 2017 | Phase 4 |
| NCT03004625 | Completed | Drug: daclatasvir|Drug: asunaprevir|Drug: Ribavirin | Hepatitis C | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | November 2016 | Phase 3 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
